Neurological outcomes in symptomatic congenital cytomegalovirus-infected infants after introduction of newborn urine screening and antiviral treatment

Brain and Development

Volumn 38, Issue 2, 2016, Pages 209-216

  Nishida, Kosuke ^a   Morioka, Ichiro ^a   Nakamachi, Yuji ^a   Kobayashi, Yoko ^a   Imanishi, Takamitsu ^a   Kawano, Seiji ^a   Iwatani, Sota ^a   Koda, Tsubasa ^a   Deguchi, Masashi ^a   Tanimura, Kenji ^a   Yamashita, Daisuke ^a   Nibu, Ken ichi ^a   Funakoshi, Toru ^b   Ohashi, Masanobu ^c   Inoue, Naoki ^d   Iijima, Kazumoto ^a   Yamada, Hideto ^a  

^a KOBE UNIVERSITY HOSPITAL   (Japan)

^b KOBE CHILDREN S HOSPITAL   (Japan)

^c Nadeshiko Ladies Hospital   (Japan)

^d GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Hospital based study; Japanese cohort; Neurological impairment; Newborn urine screening; Valganciclovir

Indexed keywords

ANTIVIRUS AGENT; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS DNA;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; GENITAL BLEEDING; HUMAN; INFANT; JAPANESE (PEOPLE); NEUROLOGIC DISEASE; NEUTROPENIA; NEWBORN; NEWBORN SCREENING; NONHUMAN; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; SYMPTOMATOLOGY; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GENETICS; JAPAN; MALE; PROCEDURES; URINE;

ANTIVIRAL AGENTS; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; INFANT, NEWBORN; JAPAN; MALE; NEONATAL SCREENING; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 84951568810     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2015.08.003     Document Type: Article

References (18)

1. Lazzarotto T., Lanari M. Why is cytomegalovirus the most frequent cause of congenital infection?. Expert Rev Anti Infect Ther 2011, 9:841-843.
2. Stagno S., Whitley R.J. Herpesvirus infections of pregnancy. Part I: cytomegalovirus and Epstein-Barr virus infections. N Engl J Med 1985, 313:1270-1274.
3. Boppana S.B., Fowler K.B., Vaid Y., Hedlund G., Stagno S., Britt W.J., et al. Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatrics 1997, 99:409-414.
4. Kylat R.I., Kelly E.N., Ford-Jones E.L. Clinical findings and adverse outcome in neonates with symptomatic congenital cytomegalovirus (SCCMV) infection. Eur J Pediatr 2006, 165:773-778.
5. Dreher A.M., Arora N., Fowler K.B., Novak Z., Britt W.J., Boppana S.B., et al. Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection. J Pediatr 2014, 164:855-859.
6. Koyano S., Inoue N., Oka A., Moriuchi H., Asano K., Ito Y., et al. Screening for congenital cytomegalovirus infection using newborn urine samples collected on filter paper: feasibility and outcomes from a multicentre study. BMJ Open 2011, 1:e000118.
7. Yamada H., Tairaku S., Morioka I., Sonoyama A., Tanimura K., Deguchi M., et al. Nationwide survey of mother-to-child infections in Japan. J Infect Chemother 2015, 21:161-164.
8. Kimberlin D.W., Lin C.Y., Sanchez P.J., Demmler G.J., Dankner W., Shelton M., et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003, 143:16-25.
9. Oliver S.E., Cloud G.A., Sanchez P.J., Demmler G.J., Dankner W., Shelton M., et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol 2009, 46(Suppl. 4):S22-S26.
10. Lombardi G., Garofoli F., Villani P., Tizzoni M., Angelini M., Cusato M., et al. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. Eur J Clin Microbiol Infect Dis 2009, 28:1465-1470.
11. Amir J., Wolf D.G., Levy I. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur J Pediatr 2010, 169:1061-1067.
12. Kimberlin D.W., Jester P.M., Sanchez P.J., Ahmed A., Arav-Boger R., Michaels M.G., et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 2015, 372:933-943.
13. Kobayashi Y., Morioka I., Koda T., Nakamachi Y., Okazaki Y., Noguchi Y., et al. Low total IgM values and high cytomegalovirus loads in the blood of newborns with symptomatic congenital cytomegalovirus infection. J Perinat Med 2015, 43:239-243.
14. Matsuo K., Morioka I., Oda M., Kobayashi Y., Nakamachi Y., Kawano S., et al. Quantitative evaluation of ventricular dilatation using computed tomography in infants with congenital cytomegalovirus infection. Brain Dev 2014, 36:10-15.
15. Itabashi K., Miura F., Uehara R., Nakamura Y. New Japanese neonatal anthropometric charts for gestational age at birth. Pediatr Int 2014, 56:702-708.
16. Kimberlin D.W., Acosta E.P., Sanchez P.J., Sood S., Agrawal V., Homans J., et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008, 197:836-845.
17. Kono Y., Mishina J., Sato N., Watanabe T., Honma Y. Developmental characteristics of very low-birthweight infants at 18months' corrected age according to birthweight. Pediatr Int 2008, 50:23-28.
18. Townsend C.L., Peckham C.S., Tookey P.A. Surveillance of congenital cytomegalovirus in the UK and Ireland. Arch Dis Child Fetal Neonatal Ed 2011, 96:F398-F403.